Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 146940
Corporate User License Price USD 6000
Corporate User License Price INR 440820
Site License Price USD 4000
Site License Price INR 293880
Request a Quote

Report Title

Neisseria meningitidis Infections-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Neisseria meningitidis Infections-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Neisseria meningitidis Infections-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Neisseria meningitidis Infections-Pipeline Review, H1 2017



Executive Summary

Neisseria meningitidis Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections-Pipeline Review, H1 2017, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 2, 2, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 4 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neisseria meningitidis Infections-Overview

Neisseria meningitidis Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neisseria meningitidis Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neisseria meningitidis Infections-Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

China National Pharmaceutical Group Corp

GlaxoSmithKline Plc

Griffith University

ImmunoBiology Ltd

JN-International Medical Corp

MGB Biopharma Ltd

Panacea Biotec Ltd

Pfizer Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Wellstat Vaccines LLC

Neisseria meningitidis Infections-Drug Profiles

(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae [serotype B] + meningococcal) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MenBioVax-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal (tetravalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W, Y] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W-135, Y] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W135] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes C, Y] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [strain C2135] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal vaccine 2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGBBP-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis [serotype B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-10-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neisseria meningitidis Infections-Dormant Projects

Neisseria meningitidis Infections-Discontinued Products

Neisseria meningitidis Infections-Product Development Milestones

Featured News & Press Releases

Mar 24, 2017: Pfizer Receives Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease

Oct 19, 2016: CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA (Meningococcal Group B Vaccine)

Sep 05, 2016: ‘Real world' data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme

May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine)

May 13, 2016: GSK's Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children

May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting

Oct 09, 2015: Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents

Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine)

Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age

Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines

May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil

Mar 29, 2015: GSK statement on meningitis vaccination in the UK

Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents

Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Neisseria meningitidis Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Neisseria meningitidis Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neisseria meningitidis Infections-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Neisseria meningitidis Infections-Pipeline by Biological E Ltd, H1 2017

Neisseria meningitidis Infections-Pipeline by China National Pharmaceutical Group Corp, H1 2017

Neisseria meningitidis Infections-Pipeline by GlaxoSmithKline Plc, H1 2017

Neisseria meningitidis Infections-Pipeline by Griffith University, H1 2017

Neisseria meningitidis Infections-Pipeline by ImmunoBiology Ltd, H1 2017

Neisseria meningitidis Infections-Pipeline by JN-International Medical Corp, H1 2017

Neisseria meningitidis Infections-Pipeline by MGB Biopharma Ltd, H1 2017

Neisseria meningitidis Infections-Pipeline by Panacea Biotec Ltd, H1 2017

Neisseria meningitidis Infections-Pipeline by Pfizer Inc, H1 2017

Neisseria meningitidis Infections-Pipeline by Sanofi Pasteur SA, H1 2017

Neisseria meningitidis Infections-Pipeline by Serum Institute of India Ltd, H1 2017

Neisseria meningitidis Infections-Pipeline by Wellstat Vaccines LLC, H1 2017

Neisseria meningitidis Infections-Dormant Projects, H1 2017

Neisseria meningitidis Infections-Dormant Projects, H1 2017 (Contd..1), H1 2017

Neisseria meningitidis Infections-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Beijing Minhai Biotechnology Co Ltd, Biological E Ltd, China National Pharmaceutical Group Corp, GlaxoSmithKline Plc, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Wellstat Vaccines LLC

Neisseria meningitidis Infections Therapeutic Products under Development, Key Players in Neisseria meningitidis Infections Therapeutics, Neisseria meningitidis Infections Pipeline Overview, Neisseria meningitidis Infections Pipeline, Neisseria meningitidis Infections Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand